Table 1 Demographics and clinical baseline characteristics
Characteristics | Total (n = 363) | Early ART arm (n = 169) | Deferred ART arm (n = 194) | p-value |
|---|---|---|---|---|
Demographic characteristics | ||||
Male, n (%) | 296 (81.5) | 138 (81.7) | 158 (81.4) | 1.000 |
Ethnic group, Han, n (%) | 345 (95.0) | 160 (94.7) | 185 (95.4) | 0.954 |
Age, (years, IQR) | 47.0 (34.0, 55.0) | 44.0 (34.0, 52.5) | 48.5 (35.0, 56.0) | 0.034 |
Smoking, n (%) | 142 (39.1) | 50 (29.6) | 92 (47.4) | 0.001 |
Alcohol use, n (%) | 94 (25.9) | 38 (22.5) | 56 (28.9) | 0.206 |
BMI, (kg/m2, IQR) | 20.2 (18.7, 22.5) | 20.2 (18.7, 22.9) | 20.2 (18.6, 22.3) | 0.780 |
Respiration, (times/min, IQR) | 22 (20, 25) | 22 (20, 25) | 22 (21, 24) | 0.715 |
Temperature, (℃, IQR) | 37.0 (36.5, 38.0) | 37.0 (36.6, 38.0) | 37.0 (36.5, 38.0) | 0.906 |
Laboratory results | ||||
Red blood cell count (× 109 /L, IQR) | 4.0 (3.6, 4.4) | 4.1 (3.7, 4.5) | 3.9 (3.5, 4.3) | 0.022 |
Platelets (× 109/L, IQR) | 228.0 (171.0, 287.0) | 224.0 (173.0, 287.5) | 231.0 (169.8, 286.5) | 0.644 |
White blood cell count (× 109 /L, IQR) | 5.6 (4.1, 7.8) | 5.7 (4.0, 8.2) | 5.4 (4.3, 7.2) | 0.474 |
ALT (U/L, IQR) | 24 (15, 38) | 24 (14, 44) | 22 (15, 37) | 0.303 |
AST (U/L, IQR) | 35 (24, 48) | 35 (24, 48) | 34 (25, 46) | 0.978 |
Total bilirubin (μmol/L, IQR) | 8.2 (6.0, 11.4) | 7.9 (5.9, 10.9) | 8.5 (6.2, 11.6) | 0.220 |
Creatinine (μmol/L, IQR) | 63.1 (53.1, 73.3) | 63.2 (53.6, 74.0) | 63.1 (52.3, 72.1) | 0.689 |
BUN (mmol/L, IQR) | 4.6 (3.5, 6.1) | 4.8 (3.6, 6.4) | 4.6 (3.3, 5.9) | 0.245 |
PaO2, (kPa, IQR) | 61.0 (53.0, 66.0) | 62.0 (53.0, 67.0) | 59.0 (52.8, 65.0) | 0.118 |
Beta-1,3-glucan (pg/ml, IQR) | 254.5 (99.2, 596.7) | 252.1 (98.7, 606.7) | 256.1 (98.7, 568.9) | 0.847 |
CD4+ T-cell count (cells/μL, IQR) | 24.0 (13.0, 44.8) | 22.8 (13.0, 44.3) | 24.5 (13.0, 45.5) | 0.653 |
CD4/CD8 ratio (IQR) | 0.08 (0.05, 0.14) | 0.07 (0.04, 0.14) | 0.09, (0.05, 0.14) | 0.288 |
HIV RNA (log10 copies/mL, IQR) | 5.6 (5.3, 6.0) | 5.6 (5.2, 6.0) | 5.6 (5.3, 6.0) | 0.424 |
Treatment strategy | ||||
ART regimens containing INSTIs, n (%) | 148 (40.8) | 71 (42.0) | 77 (39.7) | 0.732 |